TLR agonist–Stat3 siRNA conjugates: cell-specific gene silencing and enhanced antitumor immune responses

Efficient delivery of siRNA to specific cell populations in vivo remains a formidable challenge to its successful therapeutic application. We describe a novel siRNA-based approach – synthetically linking siRNA to an oligonucleotide TLR9 agonist – that targets and silences genes in TLR9(+) myeloid ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Kortylewski, Marcin, Swiderski, Piotr, Herrmann, Andreas, Wang, Lin, Kowolik, Claudia, Kujawski, Maciej, Lee, Heehyoung, Scuto, Anna, Liu, Yong, Yang, Chunmei, Deng, Jiehui, Soifer, Harris S., Raubitschek, Andrew, Forman, Stephen, Rossi, John J., Pardoll, Drew M., Jove, Richard, Yu, Hua
Formato: Texto
Lenguaje:English
Publicado: 2009
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2846721/
https://www.ncbi.nlm.nih.gov/pubmed/19749770
http://dx.doi.org/10.1038/nbt.1564

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2846721/
https://www.ncbi.nlm.nih.gov/pubmed/19749770
http://dx.doi.org/10.1038/nbt.1564

Ejemplares similares